Cognitive disorder+1
Not recruitingStudy on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients
Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients
- Disease:Cognitive disorderSchizophrenia
- Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
Poland- Participants:18–64 years
- Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
- Sponsor:Recognify Life Sciences Inc.












